Diverse alterations associated with resistance to KRAS(G12C) inhibition is a research paper published in Nature (2021). On theSindex it has a DataRank of 0.919. It has been cited 458 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.919
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →National Institutes of Health
Grant: 3UL1TR000457-08S1
Clinical and Translational Science Center
National Institutes of Health
Grant: 5T32GM007739-30
Weill Cornell/Rockefeller/Sloan-Kettering MST Program
National Institutes of Health
Grant: 2P30CA008748-43
MOUSE GENETICS
National Institutes of Health
Grant: 1F30CA232549-01
Dissecting the evolution of targeted therapy resistance in BRAFV600E-mutant cancer
National Institutes of Health
Grant: 5K08CA191082-02
Elucidating the regulation of mitosis by BRAF V600E in lung cancer
National Institutes of Health
Grant: 3P50CA247749-05S1
MSK SPORE in Genomic Instability in Breast Cancer
National Institutes of Health
Grant: 5U54OD020355-04
MSKCC Pilot Center for Precision Disease Modeling
Fields of Study
Keywords
Sustainable Development Goals
Additional file 1 of DNA replication stress and mitotic catastrophe mediate sotorasib addiction in KRASG12C-mutant cancer
Additional file 1 of DNA replication stress and mitotic catastrophe mediate sotorasib addiction in KRASG12C-mutant cancer
Additional file 1 of KRAS-mutant non-small cell lung cancer (NSCLC) therapy based on tepotinib and omeprazole combination
Additional file 1 of KRAS-mutant non-small cell lung cancer (NSCLC) therapy based on tepotinib and omeprazole combination
Additional file 1 of Dual inhibition of SUMOylation and MEK conquers MYC-expressing KRAS-mutant cancers by accumulating DNA damage
Additional file 1 of Dual inhibition of SUMOylation and MEK conquers MYC-expressing KRAS-mutant cancers by accumulating DNA damage
Additional file 2 of Dual inhibition of SUMOylation and MEK conquers MYC-expressing KRAS-mutant cancers by accumulating DNA damage
Additional file 2 of Dual inhibition of SUMOylation and MEK conquers MYC-expressing KRAS-mutant cancers by accumulating DNA damage